Is hydroxychloroquine beneficial for COVID-19 patients?

被引：61
|
作者：
Li, Xing [1 ]
Wang, Ying [2 ]
Agostinis, Patrizia [3 ]
Rabson, Arnold [4 ]
Melino, Gerry [5 ]
Carafoli, Ernesto [6 ]
Shi, Yufang [2 ,7 ]
Sun, Erwei [1 ,8 ]
机构：
[1] Southern Med Univ, Affiliated Hosp 3, Dept Rheumatol & Immunol, 183 Zhongshan Ave West, Guangzhou 510630, Guangdong, Peoples R China
[2] Chinese Acad Sci, Shanghai Inst Nutr & Hlth, Shanghai Inst Biol Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China
[3] Katholieke Univ Leuven, VIB KU Leuven Ctr Canc Biol, Leuven, Belgium
[4] Rutgers State Univ, Robert Wood Johnson Med Sch, Child Hlth Inst New Jersey, New Brunswick, NJ USA
[5] Univ Roma Tor Vergata, TOR, I-00133 Rome, Italy
[6] Univ Padua, Venetian Inst Mol Med, Rome, Italy
[7] Soochow Univ, State Key Lab Radiat Med & Protect, Affiliated Hosp 1, Inst Translat Med,Med Coll, Suzhou, Peoples R China
[8] Southern Med Univ, Shunde Hosp, Dept Rheumatol & Immunol, Peoples Hosp Shunde 1, Foshan 528000, Guangdong, Peoples R China
来源：
CELL DEATH & DISEASE | 2020年 / 11卷 / 07期
关键词：
ANTIMALARIAL-DRUGS; CHLOROQUINE; INFECTION; INHIBIT; CELLS;
D O I：
10.1038/s41419-020-2721-8
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019. As similar cases rapidly emerged around the world(1-3), the World Health Organization (WHO) declared a public health emergency of international concern on January 30, 2020 and pronounced the rapidly spreading coronavirus outbreak as a pandemic on March 11, 2020(4). The virus has reached almost all countries of the globe. As of June 3, 2020, the accumulated confirmed cases reached 6,479,405 with more than 383,013 deaths worldwide. The urgent and emergency care of COVID-19 patients calls for effective drugs, in addition to the beneficial effects of remdesivir(5), to control the disease and halt the pandemic.
引用
收藏
页数：6
相关论文
共 50 条
  • [21] COVID-19 AND QTC: IS HYDROXYCHLOROQUINE WORTH THE RISK? A REVIEW OF QT PROLONGATION IN HOSPITALISED COVID-19 PATIENTS TREATED WITH HYDROXYCHLOROQUINE AND AZITHROMYCIN
    Pollock, A.
    Kumar, R.
    Devitt, P.
    Kent, B.
    Daly, C.
    HEART, 2020, 106 : A1 - A1
  • [22] Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit
    Monti, Sara
    Montecucco, Carlomaurizio
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (06)
  • [23] COVID-19 Pneumonia in Patients on Chronic Hydroxychloroquine Therapy: Three Cases of COVID-19 Pneumonia
    Rahman, Awan K.
    Purdy, Adam G.
    Ender, Peter T.
    CASE REPORTS IN INFECTIOUS DISEASES, 2020, 2020
  • [24] The widely promoted antimalarial drug hydroxychloroquine confers nomortality benefit in hospitalized patients with COVID-19: comment on the 'Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19'
    Liuzzo, Giovanna
    Patrono, Carlo
    EUROPEAN HEART JOURNAL, 2020, 41 (46) : 4389 - 4390
  • [25] Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19
    Ruiz, S.
    Concordet, D.
    Lanot, T.
    Georges, B.
    Goudy, P.
    Baklouti, S.
    Mane, C.
    Losha, E.
    Vinour, H.
    Rousset, D.
    Lavit, M.
    Minville, V
    Conil, J-M
    Gandia, P.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 57 (02)
  • [26] Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19
    Kara, Emre
    Demirkan, Kutay
    Unal, Serhat
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 56 (03)
  • [27] The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients
    Luis Ayerbe
    Carlos Risco-Risco
    Salma Ayis
    Internal and Emergency Medicine, 2020, 15 : 1501 - 1506
  • [28] Clarifying the record on hydroxychloroquine for the treatment of patients hospitalized with COVID-19
    Rosenberg, Eli S.
    Holtgrave, David R.
    Udo, Tomoko
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 99 : 38 - 39
  • [29] Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
    Arshad, Samia
    Kilgore, Paul
    Chaudhry, Zohra S.
    Jacobsen, Gordon
    Wang, Dee Dee
    Huitsing, Kylie
    Brar, Indira
    Alangaden, George J.
    Ramesh, Mayur S.
    McKinnon, John E.
    O'Neill, William
    Zervos, Marcus
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 97 : 396 - 403
  • [30] The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin
    Chorin, Ehud
    Dai, Matthew
    Shulman, Eric
    Wadhwani, Lalit
    Bar-Cohen, Roi
    Barbhaiya, Chirag
    Aizer, Anthony
    Holmes, Douglas
    Bernstein, Scott
    Spinelli, Michael
    Park, David S.
    Chinitz, Larry A.
    Jankelson, Lior
    NATURE MEDICINE, 2020, 26 (06) : 808 - 809
12345